AstraZeneca (LSE:AZN) 12-1 Month Momentum %

: -13.44% (As of Today)

View and export this data going back to 1993. Start your Free Trial

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-16), AstraZeneca's 12-1 Month Momentum % is -13.44%.

The industry rank for AstraZeneca's 12-1 Month Momentum % or its related term are showing as below:

LSE:AZN's 12-1 Month Momentum % is ranked worse than
55.78% of 1108 companies
in the Drug Manufacturers industry
Industry Median: -8.22 vs LSE:AZN: -13.44

Competitive Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca 12-1 Month Momentum % Distribution

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where AstraZeneca's 12-1 Month Momentum % falls into.

AstraZeneca (LSE:AZN) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca (LSE:AZN) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

AstraZeneca 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of AstraZeneca's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca (LSE:AZN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (LSE:AZN) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN:Sweden AZNN:Mexico AZNl:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.